Upadacitinib for treating moderate to severe rheumatoid arthritis
Closed for comments This consultation ended on at Request commenting lead permission
5 Proposed date for review of guidance
5.1 NICE proposes that the guidance on this technology is considered for review by the guidance executive 3 years after publication of the guidance. NICE welcomes comment on this proposed date. The guidance executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.
Gary McVeigh
Chair, appraisal committee
January 2020
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions